Study of Gut Microbiota to Find Biomarkers for Spondyloarthritis in Adults with Crohns Disease

What this Trial Is About

This research aims to identify specific fecal microbiota biomarkers associated with spondyloarthritis in patients who have Crohns disease. It includes comparing the gut microbiota, serum cytokines, and peripheral blood mononuclear cells PBMC among three patient groups those with Crohns disease alone, those with spondyloarthritis alone, and those with both conditions. A group of healthy individuals without these diseases will serve as a comparison. The study uses next-generation sequencing NGS to analyze fecal microbiota, including bacterial, viral, and fungal components. Participants will be divided into four groups patients with Crohns disease only, patients with spondyloarthritis only, patients with both conditions, and healthy controls. The study involves sequencing the fecal microbiota using bacteriome, virome, and fungome NGS technologies to assess differences among these groups. This is a non-randomized, parallel design study focusing primarily on screening and analyzing microbiota diversity. During the study, participants will provide stool samples for fecal microbiota analysis. Researchers will measure changes in the diversity of bacterial, viral, and fungal populations in the gut over six months. The primary outcomes include assessing alpha and beta diversity of these microbial groups. Participants health status and medical history will be reviewed to ensure eligibility, and data collection will be performed without masking or blinding. The study is expected to be completed by December 2027.

Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease.